3-甲基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3H-咪唑并[4,5-b]吡啶 | 1257554-02-1

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 3-甲基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3H-咪唑并[4,5-b]吡啶
• 中文别名: 3-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3H-咪唑[4,5-b]吡啶
• 英文名称: 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-imidazo[4,5-b]pyridine
• 英文别名: 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[4,5-b]pyridine
• CAS: 1257554-02-1
• 化学式: C₁₃H₁₈BN₃O₂
• 分子量: 259.116
• InChiKey: NPIHDNDJLVIFGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-甲基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-3H-咪唑并[4,5-b]吡啶 在 sodium perborate tetrahydrate 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 19.83h， 生成 3-methyl-3H-imidazo[4,5-b]pyridin-6-yl benzoate
  参考文献：
  名称：

  Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

  摘要：

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.027

文献信息

• IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160009712A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及咪唑并[1,5-a]吡啶和咪唑并[1,5-a]吡嗪衍生物，这些衍生物是LSD1抑制剂，在治疗癌症等疾病中有用。
• [EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019005587A1

  公开（公告）日：2019-01-03

  The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及吡唑-4-基吡啶化合物，这些化合物是M4肌制酸乙酰胆碱受体的变构调节剂。本发明还涉及所述化合物在潜在治疗或预防M4肌制酸乙酰胆碱受体参与的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗M4肌制酸乙酰胆碱受体参与的疾病中的用途。
• Chemistry informer libraries: a chemoinformatics enabled approach to evaluate and advance synthetic methods
  作者：Peter S. Kutchukian、James F. Dropinski、Kevin D. Dykstra、Bing Li、Daniel A. DiRocco、Eric C. Streckfuss、Louis-Charles Campeau、Tim Cernak、Petr Vachal、Ian W. Davies、Shane W. Krska、Spencer D. Dreher

  DOI：10.1039/c5sc04751j

  日期：——

  We report a standardized complex molecule diagnostic approach using collections of relevant drug-like molecules which we call chemistry informer libraries.

  我们报告了一种标准化的复杂分子诊断方法，使用我们称之为化学信息库的相关类药物分子集合。
• 1H-imidazo[4,5-c]quinolinone derivatives
  申请人：Furet Pascal

  公开号：US08476294B2

  公开（公告）日：2013-07-02

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐治疗蛋白质和/或脂质激酶依赖性疾病，以及用于制造治疗该等疾病的药物制剂；1H-咪唑[4,5-c]喹啉酮衍生物用于治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗上述疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包含1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新颖的1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新颖的1H-咪唑[4,5-c]喹啉酮衍生物的方法。
• 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES
  申请人：Furet Pascal

  公开号：US20140005163A1

  公开（公告）日：2014-01-02

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐治疗蛋白质和/或脂质激酶依赖性疾病，并用于制备治疗该类疾病的药物制剂；使用1H-咪唑[4,5-c]喹啉酮衍生物治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗该类疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包含1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新型1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新型1H-咪唑[4,5-c]喹啉酮衍生物的方法。